紫杉醇联合替吉奥治疗老年进展期胃癌的疗效和安全性

Efficacy and safety of paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule in the treatment of patients with advanced gastric carcinoma

  • 摘要: 目的:探讨紫杉醇联合替吉奥(S-1)治疗老年进展期胃癌的近期疗效及毒副作用。方法36例经病理明确诊断为老年晚期胃癌患者,给予紫杉醇联合替吉奥胶囊化疗,评估其疗效和毒副作用。结果36例患者均可以评价疗效及不良反应,有效率为44.4%,疾病控制率为80.6%,中位总生存时间为9.2个月。主要不良反应为骨髓抑制和消化道反应,多为1~2级。结论紫杉醇联合替吉奥治疗老年晚期胃癌疗效肯定,且毒副作用轻,可耐受,是老年进展期胃癌患者治疗的一种最佳选择。

     

    Abstract: Objective To explore the short-term efficacy and toxic and adverse responses of paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule in the treatment of pa-tients with advanced gastric carcinoma.Methods Paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule were given to 36 elderly patients diagnosed with advanced gastric carci-noma so as to evaluate the clinical efficacy and toxic and adverse responses.Results All patients were available to evaluate the clinical efficacy and toxic and adverse responses,with response rate, disease control rate and medium survival time being 44.4%,80.6% and 9.2 months.The main ad-verse responses were myelosuppression and gastrointestinal responses in degree Ⅰ~Ⅱ.Conclusion Paclitaxel concomitant with Tegafur Gimeracil Oteracil Potassium Capsule have certain efficacy with slight toxic and adverse responses and favorable tolerance,becoming one of the optimal choices in treating elderly patients with advanced gastric carcinoma.

     

/

返回文章
返回